Innate Pharma Sa-spons Adr (IPHA) Smart Money Holdings (13F, Q2 2026)

IPHA ranks #10072 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

IPHA is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

10 institutions disclose a position in IPHA, but none treat it as a major bet — even Lion Point Capital, LP, its most concentrated holder, allocates just 0.7% of its own portfolio to it.

GAMMA Investing LLC has trimmed its IPHA position for two straight quarters, cutting it by $292.0 while still holding $15.0.

IPHA reported a net loss of $49.2M in its latest fiscal year.

• Not yet profitable — net loss of $49.2M in the latest fiscal year
• Revenue declined 55.2% year over year
• Net income improved year over year, from -$49.5M to -$49.2M
• Operating cash flow was negative, using $52.8M in cash
• Current ratio of 1.27x — below the conventional 1.5x liquidity buffer
• Total liabilities currently exceed total assets (negative shareholder equity)